Author Contributions: Drs Erne and Schoenenberger had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Erne, Burckhardt, Zuber, Buser, Dubach, Pfisterer.
Acquisition of data: Erne, Zuber, Buser, Dubach, Pfisterer.
Analysis and interpretation of data: Erne, Schoenenberger, Kiowski, Resink, Pfisterer.
Drafting of the manuscript: Erne, Schoenenberger, Resink, Pfisterer.
Critical revision of the manuscript for important intellectual content: Erne, Schoenenberger, Burckhardt, Zuber, Kiowski, Buser, Dubach, Resink, Pfisterer.
Statistical analysis: Erne, Schoenenberger, Kiowski.
Obtained funding: Erne.
Administrative, technical, or material support: Erne, Schoenenberger, Zuber, Dubach, Resink.
Study supervision: Erne, Burckhardt, Buser, Pfisterer.
Financial Disclosures: None reported.
Funding/Support: The Swiss Interventional Study on Silent Ischemia Type II was funded by a grant from the von Muralt Stiftung/Swiss Heart Foundation, Berne, Switzerland, and supported by unrestricted grants from Hoechst Pharma, Merck Pharma, and Pfizer, all in Switzerland. Dr Schoenenberger was supported by a grant from the Robert Bosch Foundation, Stuttgart, Germany.
Role of the Sponsor: None of the funding organizations or sponsors played any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Acknowledgment: We thank Marcel Zwahlen, PhD, Department of Social and Preventive Medicine, University of Berne, Berne, Switzerland, for his advice on statistical analysis. Dr Zwahlen was not compensated for his advice.